Therapeutic options for CLL include a "watch and wait" approach until the course of the disease is declared. Patients requiring treatment may be treated with a variety of chemotherapy regimens, including chlorambucil, cyclophosphamide, purine analogs like flu-darabine, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), CVP (cyclophosphamide, vincristine, prednisone), FND (fludarabine mitoxantrone, dexametha-sone), and FC (fludarabine and cyclophosphamide). Typical response rates with these treatments range from 80-90% in treatment-naive patients to 30-40% in those with relapsed or refractory disease. Currently, two monoclonal antibodies are approved for use in the United States. Rituximab (Rituxan), an anti-CD20 antibody, is approved for relapsed or refractory low-grade non-Hodgkin, CD20-positive lymphoma, including CLL/SLL. Its use in CLL sometimes results in loss of CD20 expression due to blockade of the antigen or emergence of a CD20-negative clone. Campath-IH (Alemtuzumab), which targets CD52-positive lymphocytes, is indicated for treatment of B-cell CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy.
Was this article helpful?
All you need is a proper diet of fresh fruits and vegetables and get plenty of exercise and you'll be fine. Ever heard those words from your doctor? If that's all heshe recommends then you're missing out an important ingredient for health that he's not telling you. Fact is that you can adhere to the strictest diet, watch everything you eat and get the exercise of amarathon runner and still come down with diabetic complications. Diet, exercise and standard drug treatments simply aren't enough to help keep your diabetes under control.